patient
five
patient
patient
receiv
ribavirin
intraven
corticosteroid
methylprednisolon
mgkgd
intraven
immunoglobulin
ivig
gmkgd
day
interstiti
pneumonia
develop
patient
respond
well
ribavirin
antibiot
treatment
patient
surviv
urinari
antigen
detect
pneumonia
legionella
pneumophila
serogroup
neg
seven
patient
serum
patient
posit
mycoplasma
pneumonia
immunoglobulin
ig
enzymelink
immunosorb
assay
elisa
antibodi
fourfold
increas
complement
fixat
cf
antibodi
titer
acut
convalescentphas
sera
elev
chlamydia
pneumonia
cf
antibodi
neg
reaction
c
pneumonia
igm
elisa
antibodi
found
acutephas
serum
sampl
patient
acut
convalescentphas
serum
sampl
patient
antibodi
titer
acuteand
convalescentphas
serum
sampl
c
pneumonia
c
trachomati
c
psittaci
l
pneumophila
patient
show
signific
increas
five
patient
patient
elev
cf
antibodi
level
parainfluenzaviru
cultur
influenza
viru
parainfluenzaviru
mump
respiratori
syncyti
viru
adenoviru
enteroviru
herp
simplex
viru
varicellazost
viru
cytomegaloviru
neg
variou
clinic
sampl
patient
nucleic
acid
extract
sputum
serum
sampl
infect
vero
cell
use
viral
rna
kit
qiaamp
qiagen
inc
valencia
ca
revers
transcript
polymeras
chain
reaction
rtpcr
sarscov
perform
set
primer
bniin
bnia
develop
cdc
network
laboratori
rtpcr
product
analyz
uniqu
fragment
clone
sequenc
rtpcr
test
result
sarscov
posit
oropharyng
swab
patient
sputum
patient
serum
specimen
patient
cultur
oropharyng
swab
serum
specimen
neg
cytopath
effect
vero
cell
first
found
day
day
inject
serum
specimen
patient
initi
cytopath
effect
focal
cell
round
follow
cell
detach
similar
cytopath
effect
develop
rapidli
day
day
subcultur
ultrathin
section
prepar
electron
microscopi
fix
wash
infect
vero
cell
pellet
glutaraldehyd
embed
spurr
resin
sarscov
rang
nm
diamet
identifi
electron
microscopi
figur
b
rtpcr
infect
cell
identifi
amplicon
sequenc
amplicon
patient
ident
also
ident
infect
vero
cell
genom
sarscov
genbank
access
strain
patient
nt
length
comparison
sequenc
sequenc
describ
previous
summar
tabl
number
nucleotid
differ
isol
urbani
strain
respect
igg
antibodi
sarscov
detect
standard
indirect
fluoresc
antibodi
assay
ifa
serial
serum
specimen
seven
patient
spot
slide
ifa
prepar
appli
suspens
mix
sarscovinfect
vero
cell
one
patient
patient
uninfect
cell
slide
dri
fix
aceton
conjug
use
goat
antihuman
igg
conjug
fluorescein
isothiocyan
organon
teknikacappel
turnhout
belgium
start
dilut
serum
specimen
ten
serum
sampl
obtain
pregnant
women
routin
prelabor
checkup
use
control
sera
two
ivig
product
one
domest
taiwanes
donor
one
import
bayer
leverkusen
germani
also
test
presenc
antibodi
serum
sampl
pregnant
women
two
ivig
product
neg
igg
antibodi
sarscov
six
patient
detect
igg
antibodi
sarscov
cours
ill
least
fourfold
elev
antibodi
level
acuteand
convalescentphas
serum
sampl
peak
level
rang
figur
antibodi
titer
six
patient
could
detect
day
mean
day
onset
ill
antibodi
titer
increas
plateau
day
appear
antibodi
high
antibodi
level
might
last
month
onset
ill
figur
one
previous
healthi
patient
patient
posit
sarscov
rna
rtpcr
sputum
serum
specimen
detect
antibodi
sarscov
serum
specimen
obtain
day
ill
onset
although
antibodi
level
reach
plateau
patient
viral
rna
persist
serum
sampl
patient
sputum
patient
day
onset
ill
although
four
patient
receiv
ribavirin
corticosteroid
ivig
treatment
earli
stage
diseas
antibodi
detect
earli
day
onset
ill
peak
level
antibodi
patient
patient
patient
serolog
studi
indic
antibodi
sarscov
appear
earli
day
diseas
onset
high
level
antibodi
could
last
month
diseas
onset
previou
report
indic
mean
time
igg
seroconvers
day
may
start
earli
day
find
support
result
peiri
et
al
level
appear
antibodi
sarscov
seem
influenc
use
ribavirin
immunosuppress
immunomodulatori
agent
corticosteroid
ivig
blood
product
prepar
serum
donor
per
batch
third
longterm
persist
day
ill
onset
viral
rna
serum
sputum
specimen
sarscovspecif
igg
seroconvert
import
find
prolong
shed
viral
rna
respiratori
secret
day
ill
onset
plasma
day
stool
specimen
day
document
previous
studi
need
determin
whether
viabl
viral
particl
exist
bodi
fluid
presenc
high
antibodi
viru
final
one
sar
patient
underli
coexist
condit
receiv
immunosuppress
agent
hospit
detect
antibodi
sarscov
day
day
ill
onset
serum
sputum
rtpcr
sarscov
posit
patient
sequenc
confirm
whether
patient
anerg
sarscov
infect
unknown
later
serum
sampl
taken
convalesc
stage
test
determin
whether
patient
subsequ
seroconvert
upsurg
igg
antibodi
sarscov
correl
progress
ard
necessit
ventil
support
four
seven
patient
evid
previou
studi
suggest
overexuber
host
respons
rather
uncontrol
viral
replic
contribut
sever
clinic
symptom
progress
lung
damag
whether
addit
sarscovspecif
antibodi
sar
patient
aggrav
preexist
overact
immunemedi
deterior
unclear
high
concentr
viral
rna
million
molecul
per
millilit
detect
sputum
sampl
index
patient
day
present
seri
physician
contract
infect
patient
patient
day
onset
symptom
indic
shed
viru
respiratori
tract
symptomat
sar
patient
may
last
day
viral
rna
sputum
sampl
patient
collect
day
onset
symptom
support
clinic
find
dual
infect
caus
pneumonia
sarscov
found
patient
evid
pneumonia
infect
exist
patient
cluster
find
similar
previou
report
four
patient
elev
igg
antibodi
titer
c
pneumonia
five
elev
antibodi
titer
parainfluenzaviru
acutephas
serum
sampl
without
fourfold
rise
titer
convalescentphas
serum
sampl
whether
antibodi
respons
patient
reflect
past
infect
c
pneumonia
parainfluenzaviru
mere
crossreact
antibodi
sarscov
viru
remain
unclear
may
data
complet
genom
sequenc
sarscov
strain
isol
hong
kong
singapor
china
canada
vietnam
taiwan
avail
genbank
number
nucleotid
rang
strain
sinc
februari
least
three
differ
cluster
sar
outbreak
occur
differ
part
taiwan
five
strain
identifi
patient
cluster
avail
sequenc
data
differ
strain
given
geograph
area
immedi
impact
effort
trace
origin
transmiss
sarscov
develop
novel
rapid
diagnost
test
vaccin
summari
analysi
seven
patient
virolog
serolog
document
infect
caus
sarscov
taiwan
extend
knowledg
emerg
novel
diseas
also
provid
microbiolog
immunolog
clue
physician
care
patient
suspect
disord
viral
rna
may
persist
time
patient
seroconvert
patient
may
lack
antibodi
respons
sarscov
day
ill
onset
upsurg
antibodi
respons
associ
aggrav
respiratori
failur
requir
ventil
support
